ReviewFrontiers in endocrinology2024

Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with

Youjin Oh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.